China Medical System Holdings (HKG:0867) said its New Drug Application (NDA) for ruxolitinib phosphate cream was approved by the Pharmacy & Poisons Board of Hong Kong (PPBHK), according to a Tuesday filing with the Hong Kong bourse.
The cream is used to treat adults and adolescents from 12 years of age for non-segmental vitiligo with facial involvement, the filing said.
The pharmaceutical's shares were down by 3% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。